- Home
- CIFR vs TVTX Comparison
CIFR vs TVTX Comparison
Compare CIFR & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIFR
- TVTX
- Stock Information
- Founded
- CIFR 2021
- TVTX 2008
- Country
- CIFR United States
- TVTX United States
- Employees
- CIFR N/A
- TVTX N/A
- Industry
- CIFR Investment Bankers/Brokers/Service
- TVTX Biotechnology: Pharmaceutical Preparations
- Sector
- CIFR Finance
- TVTX Health Care
- Exchange
- CIFR Nasdaq
- TVTX Nasdaq
- Market Cap
- CIFR 1.2B
- TVTX 1.4B
- IPO Year
- CIFR N/A
- TVTX N/A
- Fundamental
- Price
- CIFR $4.78
- TVTX $15.12
- Analyst Decision
- CIFR Strong Buy
- TVTX Strong Buy
- Analyst Count
- CIFR 10
- TVTX 15
- Target Price
- CIFR $7.58
- TVTX $33.57
- AVG Volume (30 Days)
- CIFR 31.8M
- TVTX 1.5M
- Earning Date
- CIFR 08-12-2025
- TVTX 07-31-2025
- Dividend Yield
- CIFR N/A
- TVTX N/A
- EPS Growth
- CIFR N/A
- TVTX N/A
- EPS
- CIFR N/A
- TVTX N/A
- Revenue
- CIFR $152,092,000.00
- TVTX $273,533,000.00
- Revenue This Year
- CIFR $88.07
- TVTX $73.84
- Revenue Next Year
- CIFR $68.21
- TVTX $46.72
- P/E Ratio
- CIFR N/A
- TVTX N/A
- Revenue Growth
- CIFR N/A
- TVTX 75.65
- 52 Week Low
- CIFR $1.86
- TVTX $7.72
- 52 Week High
- CIFR $7.99
- TVTX $25.29
- Technical
- Relative Strength Index (RSI)
- CIFR 69.24
- TVTX 44.23
- Support Level
- CIFR $3.65
- TVTX $13.97
- Resistance Level
- CIFR $4.03
- TVTX $15.30
- Average True Range (ATR)
- CIFR 0.32
- TVTX 0.71
- MACD
- CIFR 0.06
- TVTX 0.16
- Stochastic Oscillator
- CIFR 94.90
- TVTX 60.12
About CIFR Cipher Mining Inc.
Cipher Mining Inc ia an emerging technology company that operates in the Bitcoin mining ecosystem in the United States. The company is developing a cryptocurrency mining business, specializing in Bitcoin. The company is expanding and strengthening the Bitcoin network's critical infrastructure in the United States.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.